Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups based on the analysis of myeloma at the molecular level along with patient outcomes. It will provide the opportunity to identify minor translocations and mutational groups that are often poorly described because of small sample numbers and limited data sets. The project also aims to develop clinically relevant tests for disease-associated genetic mutations that will ultimately allow more tailored treatment to be given to patients in the future. Data sets from UAMS, Intergroupe Francophone du Myeloma (IFM), Dana-Farber Cancer Institute, Multiple Myeloma Research Foundation and from the national Myeloma XI are being integrated for initial characterisation and analyses and it is expected that other collaborators will contribute in the future.